AAREYDRUGS vs MARKSANS: Stock Comparison

Aarey Drugs & Pharmaceuticals Limited vs Marksans Pharma Limited

Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings

Marksans Pharma Limited is the larger company by market capitalisation. Marksans Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Marksans Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AAREYDRUGS is more favourable on 1 of 13 scored metrics and MARKSANS on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MARKSANS is the larger company
₹10,944 Cr vs ₹221 Cr
P/E Ratio
MARKSANS has a lower P/E
28.31x vs 55.36x
P/B Ratio
AAREYDRUGS has a lower P/B
1.46x vs 3.91x
EPS
MARKSANS has higher earnings per share
₹9.71 vs ₹1.47
Dividend Yield
MARKSANS has a higher dividend yield
0.29% vs 0%
Revenue Growth (TTM YoY)
MARKSANS has faster revenue growth
20.8% vs 19.8%
EPS Growth (TTM YoY)
MARKSANS has faster EPS growth
63.5% vs -41.05%
Qtr Sales Growth
MARKSANS has stronger quarterly sales growth
20.8% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAAREYDRUGSMARKSANS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAAREYDRUGSMARKSANS
Live Price₹90.51₹241.05
Day Change-4.92%-7.4%
Volume2.2 L38.22 L
52-Week High₹96₹281.6
52-Week Low₹50.31₹155
Distance from 52W High-5.72%-14.4%

Valuation

MetricAAREYDRUGSMARKSANS
Market Cap₹221 Cr₹10,944 Cr
P/E Ratio55.36x28.31x
P/B Ratio1.46x3.91x
EPS₹1.47₹9.71
Book Value₹48.67₹66.74
Dividend Yield0%0.29%

Growth

MetricAAREYDRUGSMARKSANS
Revenue Growth (TTM YoY)19.8%20.8%
EPS Growth (TTM YoY)-41.05%63.5%
Qtr Sales Growth0%20.8%
Qtr Profit Growth0%63.6%

Profitability & Leverage

MetricAAREYDRUGSMARKSANS
ROE2.64%15.2%
ROCE6%18.8%
Net Margin0.84%14.16%
Operating Margin2.21%20.4%
Debt to Equity0.33x0.11x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAAREYDRUGSMARKSANS
Promoter Holding37.71% 1.35 pp43.87%
FII Holding4.18% 0.32 pp16.76% 8.64 pp
DII Holding1.62% 1.62 pp6.57% 0.66 pp
Public Holding56.49% 0.6 pp32.79% 9.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Marksans Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.